STOCKTON, CALIFORNIA/March 6, 2013/ Newswire/ — Viratech Corp. (OTC: VIRA), the first open source biotech research social network platform, announced today the signing of an agreement for a license issued to Viratech from Health Care Intellectual Properties, LLC.
The patent is called a “Method of Making and Using a Device to Warm the Breast Prior to, and to Assist with, the Elicitation of Fluid, As Part of a Nipple Aspirate Fluid Test Kit or Part of a Breast Ductal Therapy Infusion Kit or Breast Topical Therapy Protocol,” provisional patent application number 61518691.
Each year approximately 200,000 new patients with breast cancer are diagnosed in North America, and 50,000 of those will die of the disease. Despite billions of dollars poured into research, public awareness, and improved treatment, the statistics have shown only modest improvement over the past twenty years. The slight increase in survival is attributable somewhat to earlier diagnosis but mostly to improved treatment.
According to the American Cancer Society, the current incidence of breast cancer is twelve times higher than that of cervical cancer, with a nine times higher mortality rate. The cervical Pap test, which also tests for cellular changes that are precursors for cancer, is widely credited with reducing the incidence of cervical cancer by over 80%.
The cervical Pap test is the most widely used and successful screening technology in history, with over 50 million tests performed annually in the United States, and an estimated total related expenditure of approximately $3 billion, according to a report by Medical Data International, Inc. Based on the Pap smear model, the Company believes the market potential for an effective, noninvasive breast cancer risk screening device and related tests for the breast could participate in the multi-billion dollar breast cancer testing industry.
“Early detection and treatment of breast cancer is vital to improve survival rates. Women are concerned about the rapid risk in breast cancer,” states Dr. Buckman, the CEO of Viratech . “When I first started doing breast cancer research, the chance of a women getting breast cancer sometime in her life was 1 in 25. Now it is 1 in 8, further research is needed on how to curb this sharp increase in cancer rate,” he stated.
Health Care Intellectual Properties is the holding company for Dr. Buckman’s patents licensed to Viratech on an exclusive basis. This will also allow Viratech to sub-license this technology to other companies.
Daily bombardment of damaging environmental hydrocarbons, estrogen-like compounds, carcinogens, and mercury may adversely affect breast health. In addition, detrimental factors such as the aging process, and demonstrate the need to support a healthy woman’s breast cellular structure.
Dr. Buckman has written a variety of books: Find and Stop Breast Cancer, Find and Stop Diabetes, Find and Stop Body Imbalances, The Wellness Index, and books on other health related topics.
About Viratech Corp.
Viratech Corp. has created the first open source biotech research social network platform. The purpose of the platform is to make it possible for individuals or smaller companies to compete with larger companies in the race to patent new medicines or technology. This has been made possible by leveraging social collaboration in a way that allows new biotech ventures the ability to protect their intellectual property, then simultaneously allowing those same ventures the ability to promote and crowdsource their development.
Forward-Looking Statements:
This press release includes forward-looking statements concerning the future performance of our business, its operations and its financial performance and condition, and also includes selected operating results presented without the context of accompanying financial results. These forward-looking statements include, among others, statements with respect to our objectives and strategies to achieve those objectives, as well as statements with respect to our beliefs, plans, expectations, anticipations, estimates or intentions. These forward-looking statements are based on our current expectations. We caution that all forward-looking information is inherently uncertain and actual results may differ materially from the assumptions, estimates or expectations reflected or contained in the forward-looking information, and that actual future performance will be affected by a number of factors, including economic conditions, technological change, regulatory change and competitive factors, many of which are beyond our control. Therefore, future events and results may vary significantly from what we currently foresee. We are under no obligation (and we expressly disclaim any such obligation) to update or alter the forward-looking statements whether as a result of new information, future events or otherwise.
Contact: Dr. Kevin Buckman
Viratech Corp.
http://viratech.org
Email Contact: info@viratech.org
209-477-3030